Navigation Links
Independent Investigator Initiates Phase 1 Study of Biodel's Ultra-Rapid-Acting Insulin Formulations in Patients Using Insulin Pumps
Date:5/10/2011

DANBURY, Conn., May 10, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that an independent investigator initiated a pump trial of Biodel's two ultra-rapid-acting formulations of recombinant human insulin.

The formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed mealtime insulin analogs.  This study is designed as a double blinded, three-period cross over trial in which insulin pumps will be used to deliver BIOD-105, BIOD-107 and Humalog® each at separate dosing visits in approximately 8 patients with type 1 diabetes.  This study, expected to be completed in the fourth calendar quarter of 2011, will evaluate pharmacokinetic, pharmacodynamic and injection site tolerability profiles of BIOD-105 and BIOD-107 relative to that of Humalog®.   Drs. W. Kenneth Ward and Jessica Castle of the Division of Endocrinology, Diabetes, and Clinical Nutrition at Oregon Health and Sciences University will serve as principal investigators for this trial.

Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is used as a means to provide intensive insulin therapy to patients with diabetes.  Currently available prandial insulins are used in pumps, but often are not absorbed rapidly enough to achieve optimal mealtime glucose control.  It is believed that an ultra-rapid-acting insulin will be better suited for pump therapy than currently marketed mealtime insulin analogs.

"We look forward to evaluating BIOD-105 and BIOD-107 in insulin pump patients," said Dr. W. Kenneth Ward.  "An insulin with faster absorption has the potential to better match insulin delivery with the rapid need for insulin following meals.  Such an insulin might not only allow for better glucose control with today's insulin pumps but may also help lead to a
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
4. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
6. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
7. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
8. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Promise of Vicals CMV Vaccine Noted by Independent Experts
11. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ), ... Pump, today reported its financial results for the quarter ended ... quarter of 2014 to the same period of 2013: ... million , t:slim Pump shipments grew 64 percent to ... months ended June 30, 2014 to the same period of ...
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, ... Health Care Conference, New York, NY ... Accessing Live Webcasts To access the live webcasts ...
(Date:7/31/2014)... , July 31, 2014   Auxilium Pharmaceuticals , ... specialty biopharmaceutical company, today announced that the Company will ... Thursday, August 7, 2014 before the opening of the ... conference call that day at 8:30 a.m. ET to ... 2014. The presentation slides to be used during the ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Cepheid to Webcast Upcoming Financial Presentations 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3
... III Study Provides Further Evidence of,the Significant ... Treatment,of Rheumatoid Arthritis, BASEL, Switzerland, June 6, ... multinational phase III Actemra,(tocilizumab) study, successfully reached ... proportion of patients treated with Actemra,in combination ...
... Topical Therapy Reduces TNF-alpha Production Through Inhibition,of ... 2007 /PRNewswire/ -- Anacor,Pharmaceuticals, a privately held ... placebo-controlled Phase 1 trial of,AN2728, a first-in-class ... psoriasis. The trial showed AN2728 to be,well-tolerated, ...
Cached Medicine Technology:New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 2New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 3New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 4Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2
(Date:7/31/2014)... (PRWEB) July 31, 2014 Etymotic ... announced a new sponsorship of the DrumLine Battle® ... are Etymotic’s hearing protection products ETY•Plugs® and Music•PRO® ... against the harmful effects of high-level sound. Etymotic ... sponsorship at the Drum Corps International Championships on ...
(Date:7/31/2014)... black women put concerns about their hair above their ... the U.S. Centers for Disease Control and Prevention that ... States are overweight or obese. Yet some of them ... their hair restyled or restraightened, the University of Colorado ... also noted a shift toward more "low-maintenance" hairstyles, which ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Rich Dad® ... charity yard sale to benefit Habitat for Humanity. The yard ... was raised with 100% of the proceeds donated to Habitat ... items not sold at the event were donated to the ... Road, North Fort Myers, Florida 33903. , Of the ...
(Date:7/31/2014)... aimed to diagnose pediatric patients with suspected appendicitis ... without affecting diagnostic accuracy, Mayo Clinic Children,s Center ... in the journal Surgery . , Acute ... abdominal pain in children. Appendicitis occurs when the ... scans are often used to diagnose acute appendicitis ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Insight Accelerator ... a Series A round of investment for $4.6 million ... device for collecting vital signs. The company joined ... technology to fruition with the help of Insight development ... our reason for launching the Accelerator,” says Steve McPhilliamy, ...
Breaking Medicine News(10 mins):Health News:Etymotic Research Becomes The Official Hearing Protection Sponsor Of DrumLine Battle 2Health News:Hairdo Trumps Exercise for Many Black Women, Study Finds 2Health News:Rich Dad Education Charity Yard Sale to Benefit Habitat for Humanity of Lee and Hendry Counties a Success 2Health News:Insight Accelerator Labs Advances Member Toward Commercialization 2Health News:Insight Accelerator Labs Advances Member Toward Commercialization 3
... rats finds that even one injection leads to dependent ... naturally occurring protein plays a role in the disrupted ... with drug and alcohol dependence, says a new study. ... changes in association with drug abuse, it could potentially ...
... May 28 (HealthDay News) --Should it worry you that there ... , Not especially, when you consider that there are 44 ... , This information comes to you from scientists at the ... same techniques that enabled them to map the human genetic ...
... Controlling Weight before PregnancyWHITE PLAINS, N.Y., May 28 ... right amount during pregnancy is critical to giving a ... Dimes said today in response to new guidelines from ... issued new guidelines for the amount of weight a ...
... Logistics (NGL), a premier provider of mission critical transportation, service/spare parts ... network of forward stocking locations (FSL,s). , ... Broomfield, ... provider of mission critical transportation, service/spare parts logistics , and ...
... Perot Systems, RCS advantages of increased cash flows and ... providersPLANO, Texas, May 28 Amerinet, a leading national ... PER ) ( www.perotsystems.com ) ... Systems revenue cycle solutions available to Amerinet,s acute and ...
... Patent Covers High-throughput, Anchorage-independent Assay for Screening Compounds ... Falcon Genomics, Inc. announced today that it ... covering the Company,s Cancer BioChip System (CBCS) for ... in a high-throughput in vitro setting ...
Cached Medicine News:Health News:Study Finds Multitude of Bacteria on Human Skin 2Health News:Study Finds Multitude of Bacteria on Human Skin 3Health News:New Guidelines to Fight Obesity in Pregnancy Issued 2Health News:New Guidelines to Fight Obesity in Pregnancy Issued 3Health News:NGL Expands Global Network to Service Parts Logistics Customers 2Health News:NGL Expands Global Network to Service Parts Logistics Customers 3Health News:Perot Systems to Supply Revenue Cycle Solutions to Amerinet Members Nationwide 2Health News:Perot Systems to Supply Revenue Cycle Solutions to Amerinet Members Nationwide 3Health News:Falcon Genomics Awarded Patent for Innovative Cancer Test 2
... a ubiquitous enzyme that catalyzes the ... also the specific protein that is ... (EMA) tests (Bio-Rad catalog number 29003 ... tests are highly sensitive and specific ...
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
Medicine Products: